Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio to implement 1-for-50 reverse stock split to regain Nasdaq complianceMarch 4, 2026 10:47 AM
IH Market News
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced that it will carry out a 1-for-50 reverse stock split of its common shares after filing a Certificate of Amendment in Delaware on March 3, 2026. The split is scheduled to take effect on March 6, 2026, following shareholder approval granted on February 19.The action will consolidate the company’s roughly 202.4 million outstanding shares on a proportional basis. While the number of shares in circulation will decline accordingly, the total authorized share count and shareholders’ proportional ownership will remain unchanged, aside from minor adjustments resulting from cash payments in place of fractional shares.According to the company, the reverse split was approved by the board as a measure to help restore compliance with Nasdaq’s minimum bid price requirement of $1.00. Trading will continue under the existing ticker symbol TVGN, though the shares will begin trading on a split-adjusted basis and will carry a new CUSIP identifier.The company also noted that all outstanding equity awards, warrants, and convertible preferred stock will be modified to reflect the new share ratio. The adjustment will not affect Tevogen’s underlying business operations or the total equity held by shareholders, but it is intended to support the company’s continued Nasdaq listing and potentially improve market perception.More about Tevogen Bio HoldingsTevogen Bio Holdings Inc. is a healthcare-focused company that aims to combine affordability, operational efficiency, and scientific innovation in the development of advanced therapeutics. Through its Tevogen Bio and Tevogen.AI platforms, the company integrates artificial intelligence with precision T-cell therapy technologies to develop treatments targeting areas such as virology, oncology, and neurology, while also pursuing scalable solutions for broader healthcare challenges.Tevogen Bio Holdings stock price

Original: Tevogen Bio to implement 1-for-50 reverse stock split to regain Nasdaq compliance

Thanks...🥳

Back to .42 now pump and dump complete 

Still going .59

.57 all out of.remaining 5%

.54 out of 15% kept 5%

.52

Sold 80% at .51 touch

https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24TVGN+Given+%245.0+Price+Target· Nov 20 09:203minsTevogen Bio Holdings(TVGN.US)0.4360.465+8.81%+6.63%We just received data on a new analyst forecast for $TVGN. Jason Kolbert from D. Boral Capital set a price target of 5.0 for TVGN.

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue OutlookDecember 08 2025 - 2:50PM
https://twitter.com/sharehttp://www.facebook.com/sharer.php?s=100&p[url]=https%3A%2F%2Finvestorshub.advfn.com%2Fstock-market%2FNASDAQ%2Ftevogen-bio-TVGN%2Fstock-news%2F97396706%2Ftevogen-recognized-on-2025-njbiz-power-list-amid-g
Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey’s economic and innovation landscape.NJBIZ highlighted Tevogen’s pioneering ExacTcell™ platform, its advancing pipeline in infectious diseases, oncology, and neurology, and the Company’s internally developed PredicTcell™ AI technology, designed to accelerate target prediction and improve clinical outcomes. The publication also mentioned Tevogen’s previously projected near-term commercial potential, including an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative five-year forecast of $18–22 billion.Tevogen was further recognized for its continued commitment to New Jersey’s innovation economy, including expansion which involves a 17,428-square-foot manufacturing facility and a new headquarters that more than doubles the Company’s prior footprint, centralizing R&D, regulatory, and Tevogen.AI operations.“We are honored to be recognized among New Jersey’s leading companies,” said Dr. Saadi. “This acknowledgment reflects our team’s unwavering belief in Tevogen’s mission and the future we are building together, where efficient, next-generation therapeutics can meaningfully improve patient lives.”About TevogenTevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

.49

TVGN...481...🥳

georgie18

Member Level
Re: None

Thursday, November 20, 2025 8:11:53 AM

Post#
137
of 137
TVGN...46...🥳...Gapper setting up here...imo...we shall see...

TVGN...46...🥳...Gapper setting up here...imo...we shall see...

TVGN......................................................a/h

TVGN............................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

Well, there you go you heard it from AI itself. It's gotta be true.!😊

TVGN: This firm PR's about stuff that has patently-NOTHING to do with their company!!!
https://finance.yahoo.com/news/tevogen-bio-ceo-congratulates-lynne-192400945.html

TVGN: Holy SHEEEEET!!! Look at THIS news!!! (Heck, I'm startin' to LIKE this pumpin' cheescake routine!!!)
https://finance.yahoo.com/news/tevogen-bio-ceo-congratulates-lynne-192400945.html
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

TVGN: See below what Bing's "Copilot" has to say about TVGN:

MY QUESTION FOR COPILOT: "Does Wall Street believe that TVGN's repeated PR's of late --- about BROADENING and EXPANDING their purported AI COLLABORATION with Microsoft Corp. --- are merely attempts to superficially-INFLATE the price of TVGN's STOCK?"

COPILOT'S REPLY: "It's understandable to be skeptical about such announcements. While Tevogen Bio (TVGN) has indeed expanded its AI collaboration with Microsoft, aiming to advance its PredicTcell technology and other immunotherapy treatments, some investors and analysts might view these repeated PRs as attempts to boost stock prices. However, it's important to note that the collaboration does involve significant technological advancements and potential for future growth. The stock price has seen some fluctuations, but it's also received a BUY rating from analysts, with a price target suggesting substantial upside potential. Ultimately, whether these PRs are seen as genuine efforts to advance technology or as attempts to inflate stock prices can vary among investors. It's always a good idea to do thorough research and consider multiple perspectives before making any investment decisions."

TVGN: In their 1-24-25 baloney PR, they deployed the word "DEEPEN"; and now, they deploy the word "EXPAND" their relationship with Microsoft!!! (PURE FLUFF BULLSHIT!!!)

TVGN: Identical news they had on 1-24-25. (And their FLOAT is too big.)

tvgn.............................https://stockcharts.com/h-sc/ui?s=tvgn&p=W&b=5&g=0&id=p86431144783

TVGN: Is glorious Microsoft really proactively 'collaborating' with tiny TVGN; or, is TVGN merely EXPLOITING Microsoft's already-existing AI services & products??? (Be very careful when a little-known company suddenly publishes so-called 'NEWS' with terms like 'partnering with', or 'teaming with', or 'collaborating with', or 'broadens relationship with', a well-known GOLIATH company like Microsoft --- when, in truth, the little firm is a typical punk DAVID-WITH-A-SLINGSHOT seeking Holy-Bible-like fame & fortune!!!)
https://finance.yahoo.com/news/tevogen-bio-broadens-relationship-microsoft-223400494.html
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

$TVGN $1.70 $MSFT NEWS Tevogen Bio announces AI collaboration with Microsoft PR release !!!

TVGN..............................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

TVGN....................................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

TVGN.................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

TVGN....................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

TVGN...........................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

Buyback is on

can this hit 2$ , gut says not gonna happen

See $4 zone ($4.20$4.54) as resistance now with the news eliminating debt and liabilities. Moves up slowly..
Tevogen reiterated its confidence in its financial stability, confirming sufficient available capital to fund operations for at least the next 33 months, supported by a loan agreement, which Tevogen entered into in June. Additionally, Tevogen eliminated almost all of its liabilities which were $99.9 million as reported at December 31, 2023 and now are $10.5 million as reported at September 30, 2024.





Tevogen’s internally developed intellectual property and product assets, valued internally at $10 billion+ using discounted cash flow models, are not reflected on the balance sheet. Due to US GAAP accounting rules, the company was unable to report the fair market value of its assets, including proprietary immunotherapy technologies and cutting-edge artificial intelligence platforms. The company believes that the inclusion of Tevogen’s IP assets on its balance sheet would significantly enhance its enterprise value



Commenting on the company’s performance and unique ownership structure, Dr. Saadi concluded, “Tevogen’s leadership stands apart in the biotech sector, with approximately 78% of equity retained by our officers, an extraordinary figure compared to the industry average of just 4%. In addition to our officers, our key employees have also been granted substantial restricted stock units in the company, reflecting our belief that our employees should also be owners of our success.”

TVGN.........................................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

TVGN..........................................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

Looks interesting

TVGN..................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783

$1.32 + 10% .. WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.

Adding 

https://www.stocktitan.net/news/TVGNW/tevogen-bio-expands-on-microsoft-partnership-to-integrate-machine-zepglnzxz4n7.html

Yes sir

Is it true they are partners with Microsoft?

I think I messed up. I'm sitting on 555 @ average 2.58 I really did not want to be stuck in that overnight. Thoughts?

Flip out some $2.60s 

Back in $2.20s for a flip maybe quick hopefully longer 

Not much pumped some premarket so always careful have to see if $2.29- $2.47 zone holds afee profit taking then will add some perhaps 

Can you explain what that means for me? Im new TY

TVGN 3.20 trading float about 21m about 15m traded so far 

TVGN $4s coming will trade whole float by 930am

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This WeekOctober 22 2024 - 2:30PM


Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas by the end of this week. The revenue forecast for the two therapeutic areas is approximately $1 billion each in their respective launch years. The 5-year combined estimate for the two therapeutic areas is between $28 billion and $36 billion.Tevogen Bio also plans to update shareholders on Tevogen AI, its proprietary artificial intelligence effort, designed to advance a mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations. In addition, Tevogen Bio will provide an update on clinical and commercial manufacturing.

TVGN 3.75 -3.88 zone up there and then $4.27 on high side in the 2.62-3.40 zone for now